Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
27 04 2022
Historique:
pubmed: 5 4 2022
medline: 30 4 2022
entrez: 4 4 2022
Statut: ppublish

Résumé

The measurement and interpretation of HBV DNA and RNA levels in HBV infected patients treated with antiviral therapy supports the objective of HBV disease management. Here, we quantified circulating HBV RNA through a standardized and sensitive assay in follow-up samples from both naive and treated patients as a marker of infection evolution. HBV DNA (HBV DNA for use in Cobas 6800/8800 Automated Roche Molecular Systems), RNA (Roche HBV RNA Investigational Assay for use in the Cobas 6800/8800; Roche), HBeAg and HBsAg (Elycsys HBsAg chemiluminescence immunoassay by Cobas 8000; Roche), and core-related antigen (Lumipulse G chemiluminescence assay; Fujirebio) levels were measured in cohorts of untreated or nucleos(t)ide treated, HBV-infected subjects in an outpatient hospital setting. HBV DNA levels in untreated people were 3.6 log

Identifiants

pubmed: 35377229
doi: 10.1128/spectrum.02149-21
pmc: PMC9045303
doi:

Substances chimiques

Antiviral Agents 0
Biomarkers 0
DNA, Viral 0
Hepatitis B Surface Antigens 0
RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0214921

Références

J Viral Hepat. 2019 Dec;26(12):1481-1488
pubmed: 31446638
Hepatol Commun. 2020 May 26;4(7):983-997
pubmed: 32626831
Hepatology. 2018 Dec;68(6):2106-2117
pubmed: 29734472
J Hepatol. 2017 Feb;66(2):460-462
pubmed: 27826059
J Virol. 2018 May 14;92(11):
pubmed: 29437961
Hepatology. 2020 Jul;72(1):42-57
pubmed: 31701544
Virol J. 2018 May 15;15(1):86
pubmed: 29764511
J Hepatol. 2017 Sep 21;:
pubmed: 28870671
Hepatology. 2015 Jan;61(1):66-76
pubmed: 25132147
Aliment Pharmacol Ther. 2021 Aug;54(4):462-469
pubmed: 34181772
Antivir Ther. 2018;23(8):677-685
pubmed: 30044765
Clin Microbiol Rev. 2020 Feb 26;33(2):
pubmed: 32102898
Clin Microbiol Infect. 2017 Nov;23(11):860-867
pubmed: 28288829
BMC Gastroenterol. 2019 Apr 16;19(1):53
pubmed: 30991954
J Clin Gastroenterol. 2020 Sep;54(8):e73-e82
pubmed: 32604147
Viruses. 2020 Jan 21;12(2):
pubmed: 31973017
J Viral Hepat. 2018 Sep;25(9):1038-1047
pubmed: 29633430
Viruses. 2017 Mar 21;9(3):
pubmed: 28335554
Clin Gastroenterol Hepatol. 2020 Mar;18(3):719-727.e7
pubmed: 31362119
PLoS One. 2019 Oct 4;14(10):e0222221
pubmed: 31584951
Gastroenterology. 2019 Jan;156(2):355-368.e3
pubmed: 30472225
Gut. 2021 Apr;70(4):775-783
pubmed: 32759300
J Hepatol. 2016 Jul;65(1):48-56
pubmed: 27034253
J Viral Hepat. 2020 Jun;27(6):610-619
pubmed: 32052503
Genes (Basel). 2018 Apr 12;9(4):
pubmed: 29649127
Hepatology. 2022 Feb;75(2):501-502
pubmed: 34758113
Viruses. 2021 Jan 26;13(2):
pubmed: 33530322
J Hepatol. 2019 Apr;70(4):615-625
pubmed: 30529504
Clin Infect Dis. 2021 Jun 1;72(11):2029-2031
pubmed: 32687164
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Hepatology. 2019 Apr;69(4):1816-1827
pubmed: 30362148
Genes (Basel). 2019 May 09;10(5):
pubmed: 31075974
Clin Infect Dis. 2021 Jan 27;72(2):202-211
pubmed: 31912157
J Gastroenterol Hepatol. 2018 Oct;33(10):1766-1772
pubmed: 29514418
Liver Int. 2020 Dec;40(12):2961-2971
pubmed: 32668074

Auteurs

Maria Francesca Cortese (MF)

Clinical Biochemestry, Vall D'hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Biochemistry and Microbiology, Liver Pathology Unit, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro De Investigación Biomédica En Red, Enfermedades Hepáticas y Digestvas (CIBERehd), Instituto De Salud Carlos III, Madrid, Spain.

Mar Riveiro-Barciela (M)

Centro De Investigación Biomédica En Red, Enfermedades Hepáticas y Digestvas (CIBERehd), Instituto De Salud Carlos III, Madrid, Spain.
Liver Unit, Internal Medicine Department, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

David Tabernero (D)

Biochemistry and Microbiology, Liver Pathology Unit, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro De Investigación Biomédica En Red, Enfermedades Hepáticas y Digestvas (CIBERehd), Instituto De Salud Carlos III, Madrid, Spain.

Francisco Rodriguez-Algarra (F)

The Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Adriana Palom (A)

Liver Unit, Internal Medicine Department, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

Sara Sopena (S)

Biochemistry and Microbiology, Liver Pathology Unit, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

Ariadna Rando-Segura (A)

Biochemistry and Microbiology, Liver Pathology Unit, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Virology Unit, Microbiology Department, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

Luisa Roade (L)

Liver Unit, Internal Medicine Department, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

Alison Kuchta (A)

Roche Molecular Systems, Inc., Pleasanton, California, USA.

Roser Ferrer-Costa (R)

Department of Biochemistry, Vall D'Hebron University Hospital, Barcelona, Spain.

Josep Quer (J)

Centro De Investigación Biomédica En Red, Enfermedades Hepáticas y Digestvas (CIBERehd), Instituto De Salud Carlos III, Madrid, Spain.
Digestive and Liver Disease, Vall D'hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.

Beatriz Pacin (B)

Clinical Biochemestry, Vall D'hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Biochemistry and Microbiology, Liver Pathology Unit, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro De Investigación Biomédica En Red, Enfermedades Hepáticas y Digestvas (CIBERehd), Instituto De Salud Carlos III, Madrid, Spain.

Marta Vila (M)

Clinical Biochemestry, Vall D'hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Biochemistry and Microbiology, Liver Pathology Unit, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

Rosario Casillas (R)

Clinical Biochemestry, Vall D'hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Biochemistry and Microbiology, Liver Pathology Unit, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

Selene Garcia-Garcia (S)

Clinical Biochemestry, Vall D'hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Biochemistry and Microbiology, Liver Pathology Unit, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro De Investigación Biomédica En Red, Enfermedades Hepáticas y Digestvas (CIBERehd), Instituto De Salud Carlos III, Madrid, Spain.

Rafael Esteban (R)

Centro De Investigación Biomédica En Red, Enfermedades Hepáticas y Digestvas (CIBERehd), Instituto De Salud Carlos III, Madrid, Spain.
Liver Unit, Internal Medicine Department, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

Tomás Pumarola (T)

Virology Unit, Microbiology Department, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Universitat Autònoma de Barcelona, Bellaterra, Spain.

Maria Buti (M)

Centro De Investigación Biomédica En Red, Enfermedades Hepáticas y Digestvas (CIBERehd), Instituto De Salud Carlos III, Madrid, Spain.
Liver Unit, Internal Medicine Department, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

Francisco Rodriguez-Frias (F)

Clinical Biochemestry, Vall D'hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Biochemistry and Microbiology, Liver Pathology Unit, Vall D'hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro De Investigación Biomédica En Red, Enfermedades Hepáticas y Digestvas (CIBERehd), Instituto De Salud Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH